Niraparib Treatment in Patients With Advanced Ovarian Cancer
Neoadjuvant Chemo: Insights & Its Role in Cancer Care
Pankit Vachhani, MD - Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Sacituzumab Govitecan: A New Dawn in Cancer Care
SWOG 18: Dasatinib Combo for Older Patients with Ph+ ALL - Long-Term Follow-Up
BrexucabtageneAutoleucel in Adults with Relapsed/Refractory B-Cell ALL
Onvansertib: Cardiff Oncology's First-Line Colorectal Cancer Breakthrough with Pfizer
Carrick Therapeutics: Samuraciclib + Elacestrant Phase 2 Trial in Breast Cancer
Alectinib in ALINA Trial: Phase III Adjuvant Therapy Study for Stage IB to IIIA ALK+ Non-Small Cell Lung Cancer Josin...
Amivantamab Combo in EGFR Exon 20 NSCLC: PAPILLON Results Nicolas Girard, MD
Tyrosine Kinase Inhibitors: Renal and Prostate Cancer - ESMO 2023
EGFR Mutation Progression: Second-Line Lung Cancer Treatments
Tito R. Mendoza, PhD, MS, MEd @MDAndersonNews #Immunotherapy #Cancer #Research Evaluating the psychometric properties...
Jonathan Shamash MBChB, MD, MRCP @NHSBartsHealth @NHSEnglandLDN #TesticularCancer #Cancer #Research The Impact Of A S...
Vered Stearns, MD @VeredStearns @hopkinskimmel #BreastCancer #Cancer #Research Talking An Individualized Approach To ...
Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic ...
Mechanical Conditioning score is higher in circulating tumor cells
NRG Oncology/NSABP B-51/RTOG1304 Primary Outcomes - Terry Mamounas, MD [SABCS 2023]
Cancer risk associated with exogenous hormone use in BRCA - SABCS 2023
SABCS 2023 Highlights with Virginia Kaklamani, MD
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes
Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL
Prognostic Models in Myelofibrosis Management Slides 2023
Hodgkin Lymphoma: Harnessing Hope through Advances in Research
Myelofibrosis alternative treatments - Slides 2023
Mantle Cell Lymphoma: Insights and Challenges Slides 2023
Cell Therapy for Solid Tumors: Immunotherapy Biomarkers Anusha Kalbasi, MD MOASC [2023]
Targeting Tumor Microenvironment Bridget Keenan, MD MOASC [2023]
Intratumoral Therapy Bartosz Chmielowski, MD MOASC [2023]
O-RECIST, iRECIST, ImmunoPET: Assessing Treatment Response - Anna M. Wu, MD - MOASC [2023]
OVHIPEC-1 Phase 3 Trial: Cytoreductive Surgery in Advanced Ovarian Cancer Lot Aronson, MD
Pembrolizumab + Adoptive Cell Therapy Melanoma with T-Cell data
I-SPY2 HER2+ and HER2- Precisely ID'd with 53 Gene Signatures
Bevacizumab FOLFOXIRI - Atezolizumab Metastatic Colorectal Cancer
Local Therapy for Limited Metastatic NSCLC - Targeted Therapies in Lung Cancer 2023
Adding to Targeted Therapy: Current Statistics and Biology - Targeted Therapies in Lung Cancer 2023
The Role of the Patient as Advocate - Targeted Therapies in Lung Cancer 2023
Treatment for Patients with Locally Advanced Unresectable NSCLC - Targeted Therapies in Lung Cancer
![Alectinib in ALINA Trial: Phase III Adjuvant Therapy Study for Stage IB to IIIA ALK+ Non-Small Cell Lung Cancer Josina Reddy, MD ESMO [2023]](https://oncologytubecom.cdn.ypt.me/videos/video_231124064326_vf9ce/video_231124064326_vf9ce_thumbsV2_jpg.webp?cache=1700827721_1700827721 "Alectinib in ALINA Trial: Phase III Adjuvant Therapy Study for Stage IB to IIIA ALK+ Non-Small Cell Lung Cancer Josina Reddy, MD ESMO [2023]")
![NRG Oncology/NSABP B-51/RTOG1304 Primary Outcomes - Terry Mamounas, MD [SABCS 2023]](https://oncologytubecom.cdn.ypt.me/videos/video_231208132610_v89fa/video_231208132610_v89fa_thumbsV2_jpg.webp?cache=1702060864_1702060864 "NRG Oncology/NSABP B-51/RTOG1304 Primary Outcomes - Terry Mamounas, MD [SABCS 2023]")
![Cell Therapy for Solid Tumors: Immunotherapy Biomarkers Anusha Kalbasi, MD MOASC [2023]](https://oncologytubecom.cdn.ypt.me/videos/video_231122101324_vfed5/video_231122101324_vfed5_thumbsV2_jpg.webp?cache=1700671255_1700671255 "Cell Therapy for Solid Tumors: Immunotherapy Biomarkers Anusha Kalbasi, MD MOASC [2023]")
![Targeting Tumor Microenvironment Bridget Keenan, MD MOASC [2023]](https://oncologytubecom.cdn.ypt.me/videos/video_231122091504_v3721/video_231122091504_v3721_thumbsV2_jpg.webp?cache=1700671200_1700671200 "Targeting Tumor Microenvironment Bridget Keenan, MD MOASC [2023]")
![Intratumoral Therapy Bartosz Chmielowski, MD MOASC [2023]](https://oncologytubecom.cdn.ypt.me/videos/video_231122085247_vf61f/video_231122085247_vf61f_thumbsV2_jpg.webp?cache=1700671083_1700671083 "Intratumoral Therapy Bartosz Chmielowski, MD MOASC [2023]")
![O-RECIST, iRECIST, ImmunoPET: Assessing Treatment Response - Anna M. Wu, MD - MOASC [2023]](https://oncologytubecom.cdn.ypt.me/videos/video_231121115334_v6ec8/video_231121115334_v6ec8_thumbsV2_jpg.webp?cache=1700671074_1700671074 "O-RECIST, iRECIST, ImmunoPET: Assessing Treatment Response - Anna M. Wu, MD - MOASC [2023]")
